DK1869020T3 - Heteroarylureaderivater egnet til inhibering af CHK1 - Google Patents

Heteroarylureaderivater egnet til inhibering af CHK1

Info

Publication number
DK1869020T3
DK1869020T3 DK06748900.5T DK06748900T DK1869020T3 DK 1869020 T3 DK1869020 T3 DK 1869020T3 DK 06748900 T DK06748900 T DK 06748900T DK 1869020 T3 DK1869020 T3 DK 1869020T3
Authority
DK
Denmark
Prior art keywords
heteroire
urea derivatives
derivatives suitable
inhibiting chk1
chk1
Prior art date
Application number
DK06748900.5T
Other languages
Danish (da)
English (en)
Inventor
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Adam Wade Cook
Frank Diaz
Kimba L Fisher
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DK1869020T3 publication Critical patent/DK1869020T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DK06748900.5T 2005-03-29 2006-03-29 Heteroarylureaderivater egnet til inhibering af CHK1 DK1869020T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Publications (1)

Publication Number Publication Date
DK1869020T3 true DK1869020T3 (da) 2011-01-24

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06748900.5T DK1869020T3 (da) 2005-03-29 2006-03-29 Heteroarylureaderivater egnet til inhibering af CHK1

Country Status (31)

Country Link
US (1) US8093244B2 (enExample)
EP (2) EP1869020B1 (enExample)
JP (2) JP5117374B2 (enExample)
KR (2) KR20090031459A (enExample)
CN (2) CN102219784A (enExample)
AR (1) AR056645A1 (enExample)
AT (1) ATE490248T1 (enExample)
AU (1) AU2006230337B2 (enExample)
BR (1) BRPI0609667A2 (enExample)
CA (1) CA2602199C (enExample)
CR (1) CR9395A (enExample)
CY (1) CY1111240T1 (enExample)
DE (1) DE602006018590D1 (enExample)
DK (1) DK1869020T3 (enExample)
EA (1) EA011287B1 (enExample)
ES (1) ES2356068T3 (enExample)
HR (1) HRP20100678T1 (enExample)
IL (1) IL185481A0 (enExample)
MA (1) MA29439B1 (enExample)
MX (1) MX2007012116A (enExample)
NO (1) NO20074944L (enExample)
NZ (1) NZ561458A (enExample)
PL (1) PL1869020T3 (enExample)
PT (1) PT1869020E (enExample)
RS (1) RS51616B (enExample)
SI (1) SI1869020T1 (enExample)
TN (1) TNSN07369A1 (enExample)
TW (1) TWI375559B (enExample)
UA (1) UA92164C2 (enExample)
WO (1) WO2006105262A1 (enExample)
ZA (1) ZA200707715B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
CA2673483C (en) * 2006-10-20 2014-04-08 Icos Corporation Compositions of chk1 inhibitors
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2015277212B2 (en) 2014-06-17 2020-07-02 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2019011506A (es) * 2017-03-31 2019-11-01 Seattle Genetics Inc Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
WO2021183973A1 (en) * 2020-03-13 2021-09-16 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
PT1023063E (pt) 1997-10-06 2004-02-27 Abbott Gmbh & Co Kg Derivados de indeno¬1,2-c|- nafto¬1,2-c|- e benzo¬6,7|ciclo-hepta¬1,2-c|pirazole
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Chk1キナーゼ阻害物質
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU3974001A (en) 2000-02-03 2001-08-14 Ali R. Fattaey Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001062900A1 (en) 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003004488A1 (en) 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA04010617A (es) 2002-04-26 2004-12-13 Warner Lambert Co Inhibidores de quinasa de puntos de control (wee1 y chk1).
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
EP1947102A1 (en) 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
CA2571424A1 (en) 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting chk1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
ZA200707715B (en) 2009-09-30
MX2007012116A (es) 2008-04-08
JP2009227682A (ja) 2009-10-08
CN102219784A (zh) 2011-10-19
DE602006018590D1 (de) 2011-01-13
US8093244B2 (en) 2012-01-10
RS51616B (sr) 2011-08-31
WO2006105262A1 (en) 2006-10-05
CY1111240T1 (el) 2015-06-11
TWI375559B (en) 2012-11-01
TNSN07369A1 (en) 2008-12-31
EA200702094A1 (ru) 2008-02-28
NO20074944L (no) 2007-10-24
CA2602199C (en) 2013-09-10
AU2006230337A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
NZ561458A (en) 2011-03-31
CR9395A (es) 2008-03-31
JP5117374B2 (ja) 2013-01-16
IL185481A0 (en) 2008-01-06
KR20070107178A (ko) 2007-11-06
HK1119670A1 (en) 2009-03-13
ATE490248T1 (de) 2010-12-15
HRP20100678T1 (hr) 2011-02-28
US20090143357A1 (en) 2009-06-04
MA29439B1 (fr) 2008-05-02
ES2356068T3 (es) 2011-04-04
EP1869020A1 (en) 2007-12-26
EA011287B1 (ru) 2009-02-27
JP2008535830A (ja) 2008-09-04
SI1869020T1 (sl) 2011-02-28
CN101151259B (zh) 2011-06-15
UA92164C2 (ru) 2010-10-11
CA2602199A1 (en) 2006-10-05
PL1869020T3 (pl) 2011-05-31
EP1869020B1 (en) 2010-12-01
EP2330105A1 (en) 2011-06-08
CN101151259A (zh) 2008-03-26
KR20090031459A (ko) 2009-03-25
PT1869020E (pt) 2010-12-23
BRPI0609667A2 (pt) 2010-04-20
KR100912998B1 (ko) 2009-08-20
TW200722090A (en) 2007-06-16
AU2006230337B2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1928454T3 (da) Pyridonderivater til modulering af stress-aktiveret proteinkinasesystem
DK1919907T3 (da) Heterocyklisk forbindelse
NL2000537A1 (nl) Aminederivaten.
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK2035394T3 (da) 2-pyrazincarboxamidderivater
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DK1948678T3 (da) Forbindelser til enzyminhibering
ATE520670T1 (de) Pyridazinderivate
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
IL185481A0 (en) Heteroaryl urea derivatives useful for inhibiting chk1
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
ATE452132T1 (de) Benzimidazolthiophenverbindungen als plk- inhibitoren
ATE512953T1 (de) Heterocyclische verbindungen
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate